GZT.TO Stock News Gazit Globe Ltd (GZT.TO) 14.47 08/01/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Gazit Globe Ltd (GZT.TO) 14.47 $GZT.TO

Gazit-Globe Declares a Dividend of NIS 0.45 Per Share
GlobeNewswire - Wed May 28, 3:21AM CDT
Gazit-Globe (NYSE:GZT) (TSX:GZT) (TASE:GZT), one of the world's leading multi-national real estate companies focused on acquisition, development and redevelopment of supermarket-anchored shopping centers in major urban markets, announced today that its Board of Directors has declared a quarterly cash dividend of NIS 0.45 per share of its common stock, payable on July 8, 2014 to stockholders of record as of June 25, 2014. The dividend represents an annualized distribution of NIS 1.80 per share. Since initiating its dividend in 1998, Gazit-Globe has increased its annual dividend for 15 consecutive years.

Gazit-Globe Reports First Quarter 2014 Financial Results
GlobeNewswire - Wed May 28, 3:12AM CDT
FFO Totaled NIS 151 Million; Same Property NOI Grew by 2.2%

Gazit-Globe to Report First Quarter 2014 Financial Results on May 28, 2014
GlobeNewswire - Tue May 20, 7:27AM CDT
Gazit-Globe (NYSE:TSX) (TASE:GZT), one of the world's leading multi-national real estate companies focused on acquisition, development and redevelopment of supermarket-anchored shopping centers in major urban markets, announced today that it will release its first quarter 2014 financial results on Wednesday, May 28, 2014. The financial statements will be available on the Company's website.

Gazit-Globe Reports Year-End and Fourth Quarter 2013 Financial Results
GlobeNewswire - Wed Mar 26, 4:26AM CDT
FFO and FFO Per Share Grew in 2013 by 10% and 6% Respectively; Same Property NOI Grew by 3.4%

Gazit-Globe to Report Fourth Quarter and Year-End 2013 Financial Results on March 26, 2014
GlobeNewswire - Mon Mar 17, 4:54PM CDT
Gazit-Globe (NYSE:GZT) (TSX:GZT) (TASE:GZT), one of the world's leading multi-national real estate companies focused on acquisition, development and redevelopment of supermarket-anchored shopping centers in major urban markets, announced today that it will release its fourth quarter and year-end 2013 financial results on Wednesday, March 26, 2014. The financial statements will be available on the Company's website.

Gazit-Globe's Management (GZT) Visits TSX to Celebrate Its Recent Listing; Gazit's Chairman, Chaim Katzman, Rings the Opening Bell
GlobeNewswire - Tue Feb 25, 6:48AM CST
Gazit-Globe (NYSE:GZT) (TSX:GZT) (TASE:GZT), one of the world's leading multi-national real estate companies focused on acquisition, development and redevelopment of supermarket-anchored shopping centers in major urban markets, announced that Gazit-Globe's Chairman, Chaim Katzman, Executive Vice Chairman, Dori Segal, President, Roni Soffer, and EVP and CFO, Gil Kotler, visited the Toronto Stock Exchange (TSX) yesterday to celebrate the company's recent listing of its shares. Gazit's Chairman, Chaim Katzman, rang the opening bell.

Gazit-Globe Completes a NIS 375 Million (US $107 Million) Offering of Unsecured Debentures
GlobeNewswire - Sun Dec 29, 3:06AM CST
Gazit-Globe (NYSE:GZT) (TSX:GZT) (TASE:GZT), one of the world's leading multi-national real estate companies focused on acquisition, development and redevelopment of supermarket-anchored shopping centers in major urban markets, announced today that it has completed a public offering of its existing Series K debentures in Israel. The total gross proceeds from the offering are approximately NIS 375 million (approx. US $107 million).
Scroll down for more posts ▼

Top 10 Most Recent News Articles

WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 188

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 384

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 260

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 267

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 392

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 382

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 371

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 472

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 344

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 433

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
/news?page=2">More News Articles